Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Hidden heart condition may be common in seniors with heart failure

NCT ID NCT06427304

Knowledge-focused Sponsor: Gérond'if Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looks at how often cardiac amyloidosis—a condition where abnormal proteins build up in the heart—occurs in people aged 80 and older who have been hospitalized for heart failure. Researchers will use bone scans to detect the condition in 637 participants. The goal is to find out how many of these older patients have undiagnosed cardiac amyloidosis, which could help improve future screening and care.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this could show that cardiac amyloidosis is a common, hidden cause of heart failure in older adults, leading to better screening and earlier diagnosis.
What could go wrong
This is an observational study, not a treatment trial. It will not test any therapy, and the results may not apply to all older adults with heart failure.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 637 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jul 2024

Expected to finish

Feb 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Patients with cardiac amyloidosis expressed by a positive bone scintigraphy.

Ages

80 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Aged ≥ 80 years * Hospitalised for decompensation of heart failure in the last 12 months * Subjects with hypertrophy of the septum or left ventricle at cardiac echography (defined as ≥ 12 mm) * Subjects able to undergo a bone scintigraphy scan * Subjects willing to participate Exclusion Criteria: * Subjects refusing to participate * Subjects admitted to palliative care unit. * Subjects under guardianship * Subjects with a definite diagnosis of cardiac amyloidosis

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Cardiac amyloidosis are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Amyloid Neuropathies, Familial amyloidosis heart failure

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Cardiac amyloidosis

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    36 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Ambroise Paré Hospital

    RECRUITING

    Boulogne-Billancourt, Île-de-France Region, 92100, France

  • Bretonneau Hospital

    RECRUITING

    Paris, Île-de-France Region, 75018, France

  • CHRU Nancy

    RECRUITING

    Nancy, 54000, France

  • CHRU Tours-Bretonneau Hospital

    RECRUITING

    Tours, 37000, France

  • CHU Amiens Picardie

    RECRUITING

    Amiens, 80000, France

  • CHU Angers

    RECRUITING

    Angers, 49100, France

  • CHU Bordeaux

    RECRUITING

    Bordeaux, 33000, France

  • CHU Dijon

    RECRUITING

    Dijon, 21000, France

  • CHU Grenoble Alpes

    RECRUITING

    Grenoble, 38700, France

  • CHU Lille

    RECRUITING

    Lille, 59000, France

  • CHU Limoges

    RECRUITING

    Limoges, 87000, France

  • CHU Lyon

    RECRUITING

    Lyon, 69002, France

  • CHU Marseille

    RECRUITING

    Marseille, 13005, France

  • CHU Montpellier

    RECRUITING

    Montpellier, Occitanie, 34090, France

  • CHU Nantes

    RECRUITING

    Nantes, Loire-Atlantique, 44000, France

  • CHU Nice

    RECRUITING

    Nice, 06000, France

  • CHU Orléans

    RECRUITING

    Orléans, 45100, France

  • CHU Poitiers

    RECRUITING

    Poitiers, New Aquitaine, 86000, France

  • CHU Rennes

    RECRUITING

    Rennes, 35000, France

  • CHU Rouen, Charles Nicole hospital

    RECRUITING

    Rouen, Normandy, 76000, France

  • CHU Toulouse

    RECRUITING

    Toulouse, Occitanie, 31300, France

  • CHU Trousseau-Tours

    RECRUITING

    Chambray-lès-Tours, 37170, France

  • Centre Hospitalier Intercommunal de Castres-Mazamet

    RECRUITING

    Castres, 81100, France

  • Centre Hospitalier de Carcassonne

    RECRUITING

    Carcassonne, 11100, France

  • Charles Foix Hospital

    RECRUITING

    Ivry-sur-Seine, Île-de-France Region, 94200, France

  • Clinique Saint Joseph Trelaze

    RECRUITING

    Trélazé, 49800, France

  • Clinique du Millénaire-Montpellier

    RECRUITING

    Montpellier, 34000, France

  • Corentin Celton Hospital

    NOT_YET_RECRUITING

    Issy-les-Moulineaux, Île-de-France Region, 92130, France

  • Emile Roux Hospital

    RECRUITING

    Limeil-Brévannes, Île-de-France Region, 94450, France

  • Europeen Georges Pompidou Hospital

    RECRUITING

    Paris, Île-de-France Region, 75015, France

  • GH Sud Ile-de-France

    RECRUITING

    Melun, Île-de-France Region, 77000, France

  • Geriatric Department, Broca Hospital

    RECRUITING

    Paris, IIe-de-France, 75013, France

  • Hôpital Privé Gériatrique LES SOURCES-Nice

    RECRUITING

    Nice, 06100, France

  • Lariboisière Hospital

    RECRUITING

    Paris, Île-de-France Region, 75010, France

  • Médipôle Hôpital Mutualiste Villeurbanne

    RECRUITING

    Villeurbanne, 69100, France

  • Saint Joseph Hospital

    RECRUITING

    Paris, Île-de-France Region, 75014, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.